Denosumab in breast cancer

Current Oncology Reports

Volumn 13, Issue 1, 2011, Pages 1-4

  Lipton, Allan ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Denosumab

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TAMOXIFEN; ZOLEDRONIC ACID;

ARTHRALGIA; ARTICLE; BONE CELL; BONE DENSITY; BONE DESTRUCTION; BONE METASTASIS; BONE REMODELING; BONE TURNOVER; BREAST CANCER; CANCER SURVIVAL; CELL INTERACTION; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG FEVER; HEART DISEASE; HUMAN; HYPOCALCEMIA; INFECTION; JAW OSTEONECROSIS; KIDNEY FAILURE; MYALGIA; NEPHROTOXICITY; NONHUMAN; OSTEOPENIA; OVARY INSUFFICIENCY; OVERALL SURVIVAL; POSTMENOPAUSE; TUMOR CELL;

ANTIBODIES, MONOCLONAL; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; NF-KAPPA B; OSTEOCLASTS; RANK LIGAND;

EID: 79551534789     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-010-0135-y     Document Type: Article

References (24)

1. RE Coleman 2006 Clinical features of metastatic bone disease and risk of skeletal morbidity Clin Cancer Res 12 6243s 6249s 10.1158/1078-0432.CCR-06-0931 17062708 (Pubitemid 44703797)
2. A Lipton RJ Cook P Major, et al. 2007 Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity Oncologist 12 1035 1043 1:CAS:528:DC%2BD2sXht1Krs73O 10.1634/theoncologist.12-9-1035 17914073 (Pubitemid 350007015)
3. GA Rodan 2003 The development and function of the skeleton and bone metastases Cancer 97 726 732 10.1002/cncr.11147 12548569
4. GD Roodman 2004 Mechanisms of bone metastasis N Engl J Med 350 1655 1664 1:CAS:528:DC%2BD2cXjt1WksLY%3D 10.1056/NEJMra030831 15084698 (Pubitemid 38501167)
5. DL Lacey E Timms HL Tan, et al. 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 165 176 1:CAS:528:DyaK1cXivVyhtrg%3D 10.1016/S0092-8674(00)81569-X 9568710 (Pubitemid 28180851)
6. DL Lacey HL Tan J Li, et al. 2000 Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo Am J Pathol 157 435 448 1:CAS:528:DC%2BD3cXlvFyqsro%3D 10934148
7. WS Simonet DL Lacey CR Dunstan, et al. 1997 Osteoprotegerin is a novel secreted protein involved in the regulation of bone density Cell 89 309 319 1:CAS:528:DyaK2sXislCgtLc%3D 10.1016/S0092-8674(00)80209-3 9108485
8. K Fuller B Wong S Fox, et al. 1998 TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts J Exp Med 188 997 1000 1:CAS:528:DyaK1cXmtVagtb8%3D 10.1084/jem.188.5.997 9730902 (Pubitemid 28433427)
9. H Yasuda N Shima N Nakagava, et al. 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin in osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL Proc Natl Acad Sci USA 95 3597 3601 1:CAS:528:DyaK1cXitlKjsLY%3D 10.1073/pnas.95.7.3597 9520411 (Pubitemid 28173173)
10. J Yasuda N Shima N Nakagawa, et al. 1998 Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG:OCIF inhibits osteoclastogenesis in vitro Endocrinology 139 1329 1337 10.1210/en.139.3.1329 9492069 (Pubitemid 28510154)
11. H Yasuda N Shima N Nakagawa, et al. 1999 A novel molecular mechanism modulating osteoclast differentiation and function Bone 25 109 113 1:CAS:528:DyaK1MXkvV2ru7o%3D 10.1016/S8756-3282(99)00121-0 10423033 (Pubitemid 29322072)
12. JM Blair H Zhou MJ Seibel, et al. 2006 Mechanisms of disease roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis Nat Clin Pract Oncol 3 41 49 1:CAS:528:DC%2BD28XhtVynsLo%3D 10.1038/ncponc0381 16407878 (Pubitemid 43108833)
13. GA Clines TA Guise 2005 Hypercalcemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone Endo Relat Cancer 12 549 583 1:CAS:528:DC%2BD2MXht1Sjsr3M 10.1677/erc.1.00543 (Pubitemid 41482993)
14. TA Guise KS Mohammad G Clines, et al. 2006 Basic mechanisms responsible for osteolytic and osteoblastic bone metastases Clin Cancer Res 12 6213s 6216s 1:CAS:528:DC%2BD28XhtFWhsbfO 10.1158/1078-0432.CCR-06-1007 17062703 (Pubitemid 44703792)
15. CL Shapiro J Manoola M Lbeoff 2001 Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer J Clin Oncol 19 3306 3311 1:CAS:528:DC%2BD3MXlvVamsr4%3D 11454877
16. P Hadji M Ziller DG Kieback, et al. 2009 Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomized substudy Ann Oncol 20 1203 1209 1:STN:280:DC%2BD1MvivFWkuw%3D%3D 10.1093/annonc/mdn762 19218306 This study highlights the bone loss that accompanies treatment with an aromatase inhibitor
17. GA Mincey MS Duh SK Thomas, et al. 2006 Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors Clin Breast Cancer 7 127 132 1:CAS:528: DC%2BD28XntlyrsLw%3D 10.3816/CBC.2006.n.021 16800971
18. R Eastell JE Adams RE Coleman, et al. 2008 Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen alone or in combination trial J Clin Oncol 26 1051 1057 1:CAS:528:DC%2BD1cXktVKisbo%3D 10.1200/JCO.2007.11.0726 18309940 This article details the importance of bone loss associated with long-term treatment (5 years) with an aromatase inhibitor
19. S Morony C Capparelli I Sarosi, et al. 2001 Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis Cancer Res 61 4432 4436 1:CAS:528:DC%2BD3MXktlWjsrs%3D 11389072
20. A Lipton GG Steger J Figueroa, et al. 2007 Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases J Clin Oncol 25 4431 4435 1:CAS:528: DC%2BD2sXht1ertrjP 10.1200/JCO.2007.11.8604 17785705 (Pubitemid 350013849)
21. K Fizazi A Lipton X Mariette, et al. 2009 Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates J Clin Oncol 27 1564 1572 1:CAS:528:DC%2BD1MXltVOhtr0%3D 10.1200/JCO.2008.19.2146 19237632 This article reports results of a trial comparing denosumab with continued zoledronic acid in patients who have high bone resorption on bisphosphonate therapy
22. GK Ellis HG Bone R Chlebowski, et al. 2008 Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer J Clin Oncol 26 4875 4882 1:CAS:528:DC%2BD1cXhtlGitrzO 10.1200/JCO.2008.16.3832 18725648 This article found that denosumab prevents loss of BMD associated with aromatase inhibitor therapy
23. D Hosking CE Chilvers C Christiansen, et al. 1998 Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group N Engl J Med 338 485 492 1:CAS:528:DyaK1cXhsVGju70%3D 10.1056/NEJM199802193380801 9443925 (Pubitemid 28103131)
24. Stopeck AT, Lipton A, Body JJ, et al.: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 2010, In press. This article reports results from a phase 3 trial comparing denosumab versus zoledronic acid in patients with breast cancer and bone metastases.